2 0 2 0 B U S I N E S S R E S U L T S J U L Y 3 0 , 2 0 2 0
Not for promotional use | 2 |
Not for promotional use | 3 |
• | • |
•
•
•
• | • |
•
•
•
•
Not for promotional use | 4 |
•
•
•
•
•
•
•
Not for promotional use
•
•
•
•
•
•
•
•
5
Not for promotional use | 6 |
Not for promotional use | 7 |
Not for promotional use | 8 |
Not for promotional use | 9 |
Not for promotional use | 10 |
Not for promotional use | 11 |
Not for promotional use | 12 |
Not for promotional use | 13 |
• | • | • |
•
• | • |
•
•
Not for promotional use | 14 |
• | • | • | • |
•
•
•
•
Not for promotional use | 15 |
Not for promotional use | > | 16 |
>
60% |
43% |
Semaglutide |
144 |
130 |
Semaglutide |
Not for promotional use
≥ |
17 |
KHK INHIBITOR | SARS-COV-2 MAB | |||||||||||
NASH / Diabetes | (LY-CoV016)COVID-19 | |||||||||||
CD73 INHIBITOR | NRG4 AGONIST | |||||||||||
Cancer | Heart Failure | |||||||||||
GIP/GLP COAGONIST | TAU MORPHOMER | |||||||||||
PEPTIDE Diabetes | Alzheimer's | |||||||||||
ANGPTL3/8 MAB | SSTR4 AGONIST | |||||||||||
CVD | Pain | |||||||||||
GLP-1R NPA | TRPA1 ANTAGONIST | TIRZEPATIDE | TIRZEPATIDE | |||||||||
Diabetes | Pain | Obesity | CV Outcomes | |||||||||
GGG TRI-AGONIST | D1 PAM II | ABEMACICLIB | BARICITINIB | |||||||||
Diabetes | Dementia | Adjuvant Breast Cancer | COVID-19 | |||||||||
O-GLCNACASE INH | CDK7 INHIBITOR | OLARATUMAB | BARICITINIB | BARICITINIB Systemic | ||||||||
Alzheimer's | Cancer | Pancreatic Cancer | Alopecia Areata | Lupus Erythematosus | ||||||||
N3PG Aβ MAB | ERK INHIBITOR | TIRZEPATIDE | ABEMACICLIB | MIRIKIZUMAB | MIRIKIZUMAB | |||||||
Alzheimer's | Cancer | NASH | Prostate Cancer | Crohn's Disease | Ulcerative Colitis | |||||||
PD-1 MAB AGONIST | SERD | EPIREG/TGFα MAB | SARS-COV-2 MAB | TANEZUMAB* | EMPAGLIFLOZIN* | |||||||
Immunology | Cancer | Chronic Pain | (LY-CoV555)COVID-19 | Cancer Pain | Chronic Kidney Disease | |||||||
PACAP38 MAB | IL-2 CONJUGATE | ANGIOPOIETIN 2 MAB | BTK INHIBITOR | EMPAGLIFLOZIN* | EMPAGLIFLOZIN* | |||||||
Pain | Immunology | COVID-19 | (LOXO-305)Cancer | Heart Failure pEF | Heart Failure rEF | |||||||
BTLA MAB AGONIST | GDF 15 AGONIST | CD200R MAB AGONIST | AUTOMATED INSULIN | SELPERCATINIB | SELPERCATINIB | |||||||
Immunology | Diabetes | Immunology | DELIVERY SYS Diabetes | 1L Med Thyroid Cancer | 1L NSCLC | |||||||
AUR A KINASE | OXYNTOMODULIN | BASAL INSULIN-FC | MEVIDALEN (D1 PAM) | TIRZEPATIDE | LEBRIKIZUMAB | |||||||
INHIBITOR Cancer | Diabetes | Diabetes | Dementia | Diabetes | Atopic Dermatitis | |||||||
IL-33 MAB | CXCR1/2L MAB | ZAGOTENEMAB (TAU | DONANEMAB (N3PG | SOLANEZUMAB | MIRIKIZUMAB | |||||||
Immunology | Immunology | MAB) Alzheimer's | Aβ MAB) Alzheimer's | Preclinical AD | Psoriasis | |||||||
KRAS G12C | ||||||||||||
INHIBITOR | Cancer | |||||||||||
NME | MOVEMENT SINCE | ||
April 20, 2020 | |||
NILEX | ACHIEVED MILESTONE | ||
* | Commercial | REMOVAL | |
Collaboration | |||
DULAGLUTIDE | ||
3.0 / 4.5 mg | ||
BARICITINIB | IXEKIZUMAB | |
Atopic Dermatitis | Non-Radiographic AxSpA | |
CONNECTED CARE | SELPERCATINIB | |
PREFILLED INSULIN PEN | ||
(RET INH) Cancer | ||
Diabetes | ||
TANEZUMAB* | FLORTAUCIPIR | |
Osteoarthritis Pain | Tau Imaging, diagnostic | |
✓
✓
✓
✓
✓
✓
✓-
✓
✓
Not for promotional use
New since last update
✓ | ✓ | ✓ ✓ | ||
✓ | ||||
✓ | ✓ | |||
✓ | ✓ | |||
✓ | |
✓ | |
✓ | ✓ ✓ ✓ |
✓
✓-
✓✓ ✓
✓
✓✓✓
✓
19
•
•
•
•
▪ | ▪ |
▪
▪
▪
Not for promotional use | 20 |
Not for promotional use | 22 |
Not for promotional use | 23 |
Not for promotional use | 24 |
Not for promotional use | 25 |
Not for promotional use | 26 |
•
•
•
•
Not for promotional use | 27 |
•
•
•
•
•
•
•
•
•
Not for promotional use | 28 |
Not for promotional use | 29 |
Not for promotional use | 30 |
Not for promotional use | 31 |
Not for promotional use | 32 |
Not for promotional use | 33 |
Not for promotional use | 34 |
Not for promotional use | 35 |
•
•
•
Not for promotional use | 36 |
Not for promotional use | 37 |
•
•
•
Not for promotional use | 38 |
Not for promotional use | 39 |
Not for promotional use | 40 |
<
>
Not for promotional use | 41 |
>
>
>
Not for promotional use | 42 |
Not for promotional use | 43 |
Not for promotional use | 44 |
<
<
Not for promotional use | 45 |
Not for promotional use | 46 |
Not for promotional use | 47 |
Not for promotional use | 48 |
Not for promotional use | 49 |
Not for promotional use | 50 |
Not for promotional use | 51 |
Not for promotional use | 52 |
Not for promotional use | 53 |
Not for promotional use | 54 |
≥
Not for promotional use | 55 |
Not for promotional use | 56 |
β
β
Not for promotional use | 57 |
β
Not for promotional use | 58 |
Not for promotional use | 59 |
Not for promotional use | 60 |
Attachments
- Original document
- Permalink
Disclaimer
Eli Lilly and Company published this content on 30 July 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 31 July 2020 14:46:08 UTC